[Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome].
The effects of conventional treatment for myelodysplastic syndrome (MDS) are not remarkable to date, while only a minority of patients was eligible for allogeneic stem cell transplantation. As epigenetics plays a significant role during the occurrence and development of MDS, and histone deacetylase inhibitors (HDACI), a class of gene expression modulating drugs, are currently being developed for therapy of several types of solid tumor, more attention is paying to HDACI as potential therapy of MDS. This review summarizes briefly the rationale for HDACI use in MDS, the common mechanism of HDACI, the present state of the clinical efficiency, and future development in this field.
Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Ya-Qin
YQ
Zhi
Shan-Qi
SQ
Guo
Yi-Zhuo
YZ
Zhang
D044127:Epigenesis, Genetic; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics
D056572:Histone Deacetylase Inhibitors